Alphabet’s subsidiary, Isomorphic Labs, is set to begin human trials of its AI-designed drugs, according to the company’s president Colin Murdoch. Born from DeepMind’s AlphaFold breakthrough, Isomorphic Labs combines cutting-edge AI with pharmaceutical veterans to design medicines faster, cheaper, and more accurately.
Murdoch stated that researchers are already collaborating with AI in their King’s Cross office to design cancer treatments. He expressed optimism about human clinical trials, stating that the company is “stuffing up” for this milestone and getting close.
Isomorphic Labs was spun out of DeepMind in 2021 and built on one of its most celebrated achievements: AlphaFold, an AI system capable of predicting protein structures with high accuracy. This technology has since been expanded to model interactions between proteins and other molecules like DNA and drugs.
The company’s goal is to develop a “world-class drug design engine” that combines machine learning researchers with pharmaceutical veterans. Isomorphic supports existing drug programs but also designs its own internal candidates, aiming to eventually license them after early-stage trials.
Murdoch believes his technology could improve the odds of successful drug development, reducing costs and increasing success rates. He aims to harness AlphaFold’s power to provide 100% conviction that developed drugs will work in human trials.
Source: https://fortune.com/2025/07/06/deepmind-isomorphic-labs-cure-all-diseases-ai-now-first-human-trials